Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.49 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224143 | 1.00 | CNR2 (0.49) | CNR2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25178173 | 0.86 | CNR2 (0.55) | CNR2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL26154079 | 0.85 | DRD4 (0.54) | CNR2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17224106 | 0.85 | CNR2 (0.51) | CNR2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17224103 | 0.85 | CNR2 (0.51) | CNR2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25171592 | 0.82 | CNR2 (0.53) | CNR2DRD4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2294865 | 0.81 | CNR2 (0.64) | CNR2DRD4 | |
| SCHEMBL323333 | 0.81 | CNR2 (0.64) | CNR2DRD4 | |
| SCHEMBL2298372 | 0.81 | CNR2 (0.64) | CNR2DRD4 | |
| SCHEMBL13490548 | 0.78 | DRD4 (0.52) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137459-B1 | MORPHOLIN-PYRIDINE DERIVATIVES HAVING AFFINITY TO THE TAAR1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9840501-B2 | Morpholin-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3137459-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015165835-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015165085-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | OPRM1, MC2R, OPRL1 | CNR2 40/4885DRD4 102/4885CYP1A2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.